Molecular characterization of the HIV-I gag nucleocapsid gene associated with vertical transmission

Retrovirology

Volumn 3, Issue , 2006, Pages

  Wellensiek, Brian P ^a   Sundaravaradan, Vasudha ^a   Ramakrishnan, Rajesh ^a   Ahmad, Nafees ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; EPITOPE; GAG PROTEIN; GENE PRODUCT; NUCLEOCAPSID PROTEIN; NUCLEOTIDE; VPR PROTEIN; ZIDOVUDINE; ZINC FINGER PROTEIN;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EVOLUTIONARY ADAPTATION; FEMALE; GENE FREQUENCY; GENE FUNCTION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC CONSERVATION; GENETIC HETEROGENEITY; GENETIC IDENTIFICATION; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIVIDUALITY; INFANT; LIFE CYCLE; MALE; MOLECULAR MECHANICS; NONHUMAN; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PHYLOGENETIC TREE; PHYLOGENY; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN MOTIF; VERTICAL TRANSMISSION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; BASE SEQUENCE; CLONING, MOLECULAR; DNA PRIMERS; DNA, VIRAL; FEMALE; GENE PRODUCTS, GAG; GENOME, VIRAL; HIV-1; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; NUCLEOCAPSID PROTEINS; OPEN READING FRAMES; PHYLOGENY; POLYMERASE CHAIN REACTION; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; ZINC FINGERS;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33646572593     PISSN: 17424690     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-3-21     Document Type: Article

References (70)

1. Ahmad N: The vertical transmission of human immunodeficiency virus type 1: molecular and biological properties of the virus. Crit Rev Clin Lab Sci 2005, 42:1-34.
2. Ahmad N: Molecular mechanisms of human immunodeficiency virus type 1 mother-infant transmission. Adv Pharmacol 2000, 49:387-416.
3. Ahmad N: Maternal-Fetal Transmission of Human Immunodeficiency Virus. J Biomed Sci 1996, 3:238-250.
4. Blanche S, Rouzioux C, Moscato ML, Veber F, Mayaux MJ, Jacomet C, Tricoire J, Deville A, Vial M, Firtion G: A prospective study of infants born to women seropositive for human immunodeficiency virus type 1. HIV Infection in Newborns French Collaborative Study Group. N Engl J Med 1989, 320:1643-1648.
5. Mok JQ, Giaquinto C, De Rossi A, Grosch-Worner I, Ades AE, Peckham CS: Infants born to mothers seropositive for human immunodeficiency virus. Preliminary findings from a multicentre European study. Lancet 1987, 1:1164-1168.
6. Ryder RW, Nsa W, Hassig SE, Behets F, Rayfield M, Ekungola B, Nelson AM, Mulenda U, Francis H, Mwandagalirwa K: Perinatal transmission of the human immunodeficiency virus type 1 to infants of seropositive women in Zaire. N Engl J Med 1989, 320:1637-1642.
7. Lepage P, Van de Perre P, Carael M, Nsengumuremyi F, Nkurunziza J, Butzler JP, Sprecher S: Postnatal transmission of HIV from mother to child. Lancet 1987, 2:400.
8. Mother-to-child transmission of HIV infection. The European Collaborative Study. Lancet 1988, 2:1039-1043.
9. Ahmad N, Baroudy BM, Baker RC, Chappey C: Genetic analysis of human immunodeficiency virus type 1 envelope V3 region isolates from mothers and infants after perinatal transmission. J Virol 1995, 69:1001-1012.
10. Wolinsky SM, Wike CM, Korber BT, Hutto C, Parks WP, Rosenblum LL, Kunstman KJ, Furtado MR, Munoz JL: Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants. Science 1992, 255:1134-1137.
11. Matala E, Hahn T, Yedavalli VR, Ahmad N: Biological characterization of HIV type 1 envelope V3 regions from mothers and infants associated with perinatal transmission. AIDS Res Hum Retroviruses 2001, 17:1725-1735.
12. Hahn T, Ramakrishnan R, Ahmad N: Evaluation of genetic diversity of human immunodeficiency virus type 1 NEF gene associated with vertical transmission. J Biomed Sci 2003, 10:436-450.
13. Husain M, Hahn T, Yedavalli VR, Ahmad N: Characterization of HIV type 1 tat sequences associated with perinatal transmission. AIDS Res Hum Retroviruses 2001, 17:765-773.
14. Yedavalli VR, Chappey C, Matala E, Ahmad N: Conservation of an intact vif gene of human immunodeficiency virus type 1 during maternal-fetal transmission. J Virol 1998, 72:1092-1102.
15. Yedavalli VR, Chappey C, Ahmad N: Maintenance of an intact human immunodeficiency virus type 1 vpr gene following mother-to-infant transmission. J Virol 1998, 72:6937-6943.
16. Yedavalli VR, Husain M, Horodner A, Ahmad N: Molecular characterization of HIV type 1 vpu genes from mothers and infants after perinatal transmission. AIDS Res Hum Retroviruses 2001, 17:1089-1098.
17. Yedavalli VR, Ahmad N: Low conservation of functional domains of HIV type 1 vif and vpr genes in infected mothers correlates with lack of vertical transmission. AIDS Res Hum Retroviruses 2001, 17:911-923.
18. Poon DT, Wu J, Aldovini A: Charged amino acid residues of human immunodeficiency virus type 1 nucleocapsid p7 protein involved in RNA packaging and infectivity. J Virol 1996, 70:6607-6616.
19. Zuber G, McDermott J, Karanjia S, Zhao W, Schmid MF, Barldis E: Assembly of retrovirus capsid- nucleocapsid proteins in the presence of membranes or RNA. J Virol 2000, 74:7431-7441.
20. Heath MJ, Derebail SS, Gorelick RJ, DeStefano JJ: Differing roles of the N- and C-terminal zinc fingers in human immunodeficiency virus nucleocapsid protein-enhanced nucleic acid annealing. J Biol Chem 2003, 278:30755-30763.
21. Freed EO: HIV-1 gag proteins: diverse functions in the virus life cycle. Virology 1998, 251:1-15.
22. Krishnamoorthy G, Roques B, Darlix JL, Mely Y: DNA condensation by the nucleocapsid protein of HIV-1: a mechanism ensuring DNA protection. Nucleic Acids Res 2003, 31:5425-5432.
23. Feng YX, Campbell S, Harvin D, Ehresmann B, Ehresmann C, Rein A. The human immunodeficiency virus type 1 Gag polyprotein has nucleic acid chaperone activity: possible role in dimerization of genomic RNA and placement of tRNA on the primer binding site. J Virol 1999, 73:4251-4256.
24. Rice WG, Baker DC, Schaeffer CA, Graham L, Bu M, Terpening S, Clanton D, Schultz R, Bader JP, Buckheit RW Jr, Field L, Singh PK, Turpin JA: Inhibition of multiple phases of human immunodeficiency virus type 1 replication by a dithiane compound that attacks the conserved zinc fingers of retroviral nucleocapsid proteins. Antimicrob Agents Chemother 1997, 41:419-426.
25. Azoulay J, Clamme JP, Darlix JL, Roques BP, Mely Y: Destabilization of the HIV-1 complementary sequence of TAR by the nucleocapsid protein through activation of conformational fluctuations. J Mol Biol 2003, 326:691-700.
26. McGrath CF, Buckman JS, Gagliardi TD, Bosche WJ, Coren LV, Gorelick RJ: Human cellular nucleic acid-binding protein Zn2+ fingers support replication of human immunodeficiency virus type 1 when they are substituted in the nucleocapsid protein. J Virol 2003, 77:8524-8531.
27. Heath MJ, Destefano JJ: A complementary single-stranded docking site is required for enhancement of strand exchange by human immunodeficiency virus nucleocapsid protein on substrates that model viral recombination. Biochemistry 2005, 44:3915-3925.
28. Levin JG, Guo J, Rouzina I, Musier-Forsyth K: Nucleic acid chaperone activity of HIV-1 nucleocapsid protein: critical role in reverse transcription and molecular mechanism. Prog Nucleic Acid Res Mol Biol 2005, 80:217-286.
29. Lyonnais S, Gorelick RJ, Mergny JL, Le Cam E, Mirambeau G: G-quartets direct assembly of HIV- 1 nucleocapsid protein along single-stranded DNA. Nucleic Acids Res 2003, 31:5754-5763.
30. Zhu H, Jian H, Zhao LJ: Identification of the 15FRFG domain in HIV-1 Gag p6 essential for Vpr packaging into the virion. Retrovirology 2004, 1:26.
31. Strack B, Calistri A, Craig S, Popova E, Gottlinger HG: AIPI/ALIX is a binding partner for HIV-1 p6 and EIAV p9 functioning in virus budding. Cell 2003, 114:689-699.
32. VerPlank L, Bouamr F, LaGrassa TJ, Agresta B, Kikonyogo A, Leis J, Carter CA. Tsg10l, a homologue of ubiquitin-conjugating (E2) enzymes, binds the L domain in HIV type 1 Pr55(Gag). Proc Nod Acad Sci USA 2001, 98:7724-7729.
33. Kondo E, Gottlinger HG: A conserved LXXLF sequence is the major determinant in p6gag required for the incorporation of human immunodeficiency virus type 1 Vpr. J Virol 1996, 70:159-164.
34. Bachand F, Yao XJ, Hrimech M, Rougeau N, Cohen EA: Incorporation of Vpr into human immunodeficiency virus type 1 requires a direct interaction with the p6 domain of the p55 gag precursor. J Biol Chem 1999, 274:9083-9091.
35. Goff A, Ehrlich LS, Cohen SN, Carter CA: Tsg101 control of human immunodeficiency virus type 1 Gag trafficking and release. J Virol 2003, 77:9173-9182.
36. Gottlinger HG, Dorfman T, Sodroski JG, Haseltine WA: Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release. Proc Nad Acad Sci U S A 1991, 88:3195-3199.
37. Huang M, Orenstein JM, Martin MA, Freed EO: p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease. J Virol 1995, 69:6810-6818.
38. Demirov DG, Ono A, Orenstein JM, Freed EO: Overexpression of the N-terminal domain of TSG101 inhibits HIV-1 budding by blocking late domain function. Proc Natl Acad Sci U S A 2002, 99:955-960.
39. Garrus JE, von Schwedler UK, Pornillos OW, Morham SG, Zavitz KH, Wang HE, Wettstein DA, Stray KM, Cote M, Rich RL, Myszka DG, Sundquist WI: Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. Cell 2001, 107:55-65.
40. Demirov DG, Orenstein JM, Freed EO: The late domain of human immunodeficiency virus type 1 p6 promotes virus release in a cell type-dependent manner. J Virol 2002, 76:105-117.
41. Martin-Serrano J, Yarovoy A, Perez-Caballero D, Bieniasz PD: Divergent retroviral late-budding domains recruit vacuolar protein sorting factors by using alternative adaptor proteins. Proc Natl Acad Sci U S A 2003, 100:12414-12419.
42. von Schwedler UK, Stuchell M, Muller B, Ward DM, Chung HY, Morita E, Wang HE, Davis T, He GP, Cimbora DM, Scott A, Krausslich HG, Kaplan J, Morham SG, Sundquist WI: The protein network of HIV budding. Cell 2003, 114:701-713.
43. Strack B, Calistri A, Gottlinger HG: Late assembly domain function can exhibit context dependence and involves ubiquitin residues implicated in endocytosis. J Virol 2002, 76:5472-5479.
44. Jenkins Y, Pornillos O, Rich RL, Myszka DG, Sundquist WI, Malim MH: Biochemical analyses of the interactions between human immunodeficiency virus type 1 Vpr and p6(Gag). J Virol 2001, 75:10537-10542.
45. Lu YL, Bennett RP, Wills JW, Gorelick R, Ratner L: A leucine triplet repeat sequence (LXX)4 in p6gag is important for Vpr incorporation into human immunodeficiency virus type 1 particles. J Virol 1995, 69:6873-6879.
46. Swofford DI: PAUP* Phylogenetic analysis using parsimony and other methods, vol 4.0.0b2. Sunderland, MA: Sinauer associated; 1999.
47. Posada D, CK: MODELTEST: testing the model of DNA substitution. Bioinformatics 1998, 14:817-818.
48. Nielsen R, Yang Z: Likelihood models for detecting positively selected amino acid sites and applications to the HIV-1 envelope gene. Genetics 1998, 148:929-936.
49. Yang Z: Phylogenetic Analysis of Maximum Likelihood (PAML) 3.0th edition. London UCo.; 2000.
50. Nei M, Gojobori T: Simple methods for estimating the numbers of synonymous and nonsynonymous nucleotide substitutions. Mol Biol Evol 1986, 3:418-426.
51. Sundaravaradan V, Hahn T, Ahmad N: Conservation of functional domains and limited heterogeneity of HIV-1 reverse transcriptase gene following vertical transmission. Retrovirology 2005, 2:36.
52. Dorfman T, Luban J, Goff SP, Haseltine WA, Gottlinger HG: Mapping of functionally important residues of a cysteine-histidine box in the human immunodeficiency virus type 1 nucleocapsid protein. J Virol 1993, 67:6159-6169.
53. Freed EO: Viral late domains. J Virol 2002, 76:4679-4687.
54. Peters S, Munoz M, Yerly S, Sanchez-Merino V, Lopez-Galindez C, Perrin L, Larder B, Cmarko D, Fakan S, Meylan P, Telenti A: Resistance to nucleoside analog reverse transcriptase inhibitors mediated by human immunodeficiency virus type 1 p6 protein. J Virol 2001, 75:9644-9653.
55. Ibe S, Shibata N, Utsumi M, Kaneda T: Selection of human immunodeficiency virus type 1 variants with an insertion mutation in the p6(gag) and p6(pol) genes under highly active antiretroviral therapy. Microbiol Immunol 2003, 47:71-79.
56. Yu XG, Shang H, Addo MM, Eldridge RL, Phillips MN, Feeney ME, Strick D, Brander C, Goulder PJ, Rosenberg ES, Walker BD, Altfeld M: Important contribution of p15 Gag-specific responses to the total Gag-specific CTL responses. Aids 2002, 16:321-328.
57. Wilson CC, Brown RC, Korber BT, Wilkes BM, Ruhl DJ, Sakamoto D, Kunstman K, Luzuriaga K, Hanson IC, Widmayer SM, Wiznia A, Clapp S, Ammann AJ, Koup RA, Wolinsky SM, Walker BD: Frequent detection of escape from cytotoxic T-lymphocyte recognition in perinatal human immunodeficiency virus (HIV) type 1 transmission: the ariel project for the prevention of transmission of HIV from mother to infant. J Virol 1999, 73:3975-3985.
58. HIV-1 Immunology CTL, CD8+ T cells on World Wide Web URL [http://www.hiv.lanl.gov/content/immunology/ctl_search].
59. Hahn T, Ahmad N: Genetic characterization of HIV type 1 gag p17 matrix genes in isolates from infected mothers lacking perinatal transmission. AIDS Res Hum Retroviruses 2001, 17:1673-1680.
60. Hahn T, Matala E, Chappey C, Ahmad N: Characterization of mother-infant HIV type 1 gag p17 sequences associated with perinatal transmission. AIDS Res Hum Retroviruses 1999, 15:875-888.
61. Segal DJ, Goncalves J, Eberhardy S, Swan CH, Torbett BE, Li X, Barbas CF 3rd: Attenuation of HIV-1 replication in primary human cells with a designed zinc finger transcription factor. J Biol Chem 2004, 279:14509-14519.
62. Qiu JT, Liu B, Tian C, Pavlakis GN, Yu XF: Enhancement of primary and secondary cellular immune responses against human immunodeficiency virus type 1 gag by using DNA expression vectors that target Gag antigen to the secretory pathway. J Virol 2000, 74:5997-6005.
63. Sei S, Yang QE, O'Neill D, Yoshimura K, Nagashima K, Mitsuya H: Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain. J Virol 2000, 74:4621-4633.
64. Ibe S, Hotta N, Takeo U, Tawada Y, Mamiya N, Yamanaka K, Utsumi M, Kaneda T: Prevalence of drug-resistant human immunodeficiency virus type 1 in therapy-naive patients and usefulness of genotype testing. Microbiol Immunol 2003, 47:499-505.
65. Sabbaj S, Edwards BH, Ghosh MK, Semrau K, Cheelo S, Thea DM, Kuhn L, Ritter GD, Mulligan MJ, Goepfert PA, Aldrovandi GM: Human immunodeficiency virus-specific CD8(+) T cells in human breast milk. J Virol 2002, 76:7365-7373.
66. Huelsenbeck JPCK: Phylogeny estimation and hypothesis testing using maximum likelihood. Annu Rev Ecol Sys 1997:437-466.
67. Akaike H: A new look at the statistical model identification. IEEE Trans Autom Contr 1974, 19:716-723.
68. Kuhner MK, Yamato J, Felsenstein J: Estimating effective population size and mutation rate from sequence data using Metropolis-Hastings sampling. Genetics 1995, 140:1421-1430.
69. Fetching the COALESCE program on World Wide Web URL [http://evolution.genetics.washington.edu/lamarc/coalesce.html].
70. Centers for Disease Control and Prevention Classification system for human immunodeficiency virus (HIV) in children under 13 years of age. MMWR 1987, 36:225-236.